Moldova - rumeenia - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

janssen-cilag international nv - selexipagum - comprimate filmate - 800 mcg

Euroopa Liit - rumeenia - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mielom multiplu - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopa Liit - rumeenia - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mielom multiplu - agenți antineoplazici - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopa Liit - rumeenia - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - mielom multiplu - agenți antineoplazici - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.